Stevens Katherine G, Pukala Tara L
The University of Adelaide, Adelaide, Australia.
Trends Analyt Chem. 2020 Nov;132:116064. doi: 10.1016/j.trac.2020.116064. Epub 2020 Oct 7.
Developments in immunoassays and mass spectrometry have independently influenced diagnostic technology. However, both techniques possess unique strengths and limitations, which define their ability to meet evolving requirements for faster, more affordable and more accurate clinical tests. In response, hybrid techniques, which combine the accessibility and ease-of-use of immunoassays with the sensitivity, high throughput and multiplexing capabilities of mass spectrometry are continually being explored. Developments in antibody conjugation methodology have expanded the role of these biomolecules to applications outside of conventional colorimetric assays and histology. Furthermore, the range of different mass spectrometry ionisation and analysis technologies has enabled its successful adaptation as a detection method for numerous clinically relevant immunological assays. Several recent examples of combined mass spectrometry-immunoassay techniques demonstrate the potential of these methods as improved diagnostic tests for several important human diseases. The present challenges are to continue technological advancements in mass spectrometry instrumentation and develop improved bioconjugation methods, which can overcome their existing limitations and demonstrate the clinical significance of these hybrid approaches.
免疫测定和质谱技术的发展各自独立地影响了诊断技术。然而，这两种技术都有其独特的优势和局限性，这决定了它们满足对更快、更经济且更准确的临床试验不断变化的需求的能力。作为回应，人们不断探索将免疫测定的易获取性和易用性与质谱的灵敏度、高通量和多重分析能力相结合的混合技术。抗体偶联方法的发展已将这些生物分子的作用扩展到传统比色测定法和组织学之外的应用。此外，不同的质谱电离和分析技术的范围使其成功地适用于众多临床相关免疫测定的检测方法。最近几个质谱 - 免疫测定组合技术的例子证明了这些方法作为几种重要人类疾病改进诊断测试的潜力。目前的挑战是继续推进质谱仪器的技术进步，并开发改进的生物偶联方法，以克服其现有局限性，并证明这些混合方法的临床意义。
